AAV-2 capsid-specific CD8+T cells limit the duration of gene therapy in humans and cross-react with AAV-8 capsid.

被引：0
|
作者：
Mingozzi, Federico
Maus, Marcela V.
Sabatino, Denise E.
Hui, Daniel J.
Rasko, John E. J.
Ragni, Margaret V.
Manno, Catherine Scott
Ertl, Hildegund C. J.
High, Katherine A.
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Univ Sydney, Cent Inst Canc Med & Cell Biol, Newtown, Tas, Australia
[3] Univ Penn, Med Ctr, Hemophillia Ctr W Pennsylvania, Pittsburgh, PA USA
[4] Wistar Inst Anat & Biol, Program Immunol, Philadelphia, PA 19104 USA
[5] Howard Hughes Med Inst, Philadelphia, PA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
455
引用
收藏
页码：138A / 139A
页数：2
相关论文
共 40 条
  • [21] T cell responses to AAV vector capsid limit the duration of transgene expression in humans after liver-directed gene therapy.
    Mingozzi, F
    Maus, MV
    Sabatino, DE
    Hui, D
    Manno, CS
    Ragni, MV
    High, KA
    [J]. BLOOD, 2005, 106 (11) : 855A - 855A
  • [22] Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo
    Li, Chengwen
    Hirsch, Matthew
    Asokan, Aravind
    Zeithaml, Brian
    Ma, Hong
    Kafri, Tal
    Samulski, R. Jude
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (14) : 7540 - 7547
  • [23] TLR9 and Dendritic Cells Are Required for CD8+ T Cell Responses to the AAV Capsid
    Rogers, Geoffrey L.
    Herzog, Roland W.
    [J]. BLOOD, 2014, 124 (21)
  • [24] Type I Interferon Signaling Is Essential for Cross-Presentation and Cross-Priming of CD8+ T Cells Against AAV Capsid
    Shirley, Jamie L.
    Biswas, Moanaro
    Herzog, Roland W.
    [J]. MOLECULAR THERAPY, 2017, 25 (05) : 239 - 240
  • [25] In vitro and in vivo modulation of AAV capsid CD8+T cell responses with IgG-derived MHC class II epitopes
    Hui, Daniel
    Basner-Tschakarjan, Etiena
    Chen, Yifeng
    Pien, Gary
    de Groot, Anne
    High, Katherine
    Mingozzi, Federico
    [J]. HUMAN GENE THERAPY, 2012, 23 (10) : A40 - A40
  • [26] Determination of specific CD4 and CD8 T cell epitopes after AAV2-and AAV8-hF.IX gene therapy
    Chen, J
    Wu, Q
    Yang, P
    Hsu, HC
    Mountz, JD
    [J]. MOLECULAR THERAPY, 2006, 13 (02) : 260 - 269
  • [27] Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors
    Xicluna, Rebecca
    Avenel, Allan
    Vandamme, Celine
    Devaux, Marie
    Jaulin, Nicolas
    Couzinie, Celia
    Le Duff, Johanne
    Charrier, Alicia
    Guilbaud, Mickael
    Adjali, Oumeya
    Gernoux, Gwladys
    [J]. HUMAN GENE THERAPY, 2024, 35 (9-10) : 355 - 364
  • [28] Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease
    Choi, Su Jin
    Yi, John S. S.
    Lim, Jeong-A
    Tedder, Thomas F. F.
    Koeberl, Dwight D. D.
    Jeck, William
    Desai, Ankit K. K.
    Rosenberg, Amy
    Sun, Baodong
    Kishnani, Priya S. S.
    [J]. JOURNAL OF GENE MEDICINE, 2023, 25 (08):
  • [29] Absence of CD8 T Cell Responses Against AAV Capsid Using Reduced Vector Dose or Library Selected Liver Targeted AAV2 Based Capsids
    Palaschak, Brett
    Marsic, Damien
    Markusic, David M.
    [J]. MOLECULAR THERAPY, 2015, 23 : S105 - S106
  • [30] Upregulation of CD8+regulatory T cells following liver-directed AAV gene therapy
    Gaddie, Cristina D.
    Senior, Kevin G.
    Chan, Christopher
    Hoffman, Brad E.
    Keeler, Geoffrey D.
    [J]. CELLULAR IMMUNOLOGY, 2024, 397
1234